Clinical key issues and countermeasures of CAR-T cell therapy
10.3872/j.issn.1007-385x.2025.01.002
- VernacularTitle:CAR-T细胞治疗的临床关键问题和对策
- Author:
Xinfeng CHEN
1
;
Shasha LIU
1
;
Yi ZHANG
1
Author Information
1. 郑州大学第一附属医院 生物细胞治疗中心/生物免疫治疗病区,河南 郑州 450052
- Publication Type:Journal Article
- Keywords:
immunotherapy;
chimeric antigen receptor gene-modified T lymphocyte(CAR-T cell);
tumor microenvironment;
solid tumor
- From:
Chinese Journal of Cancer Biotherapy
2025;32(1):9-13
- CountryChina
- Language:Chinese
-
Abstract:
Since 2017,twelve chimeric antigen receptor gene-modified T lymphocyte(CAR-T cell)products have been approved for the treatment of hematological malignancies,including relapsed/refractory acute B lymphoblastic leukemia(B-ALL),specific subtypes of B cell lymphoma,and multiple myeloma.However,CAR-T cell therapy faces numerous challenges in its clinical application,such as resistance,lengthy production cycles,high individuation and costs in hematological tumors,and tumor heterogeneity/antigen escape,insufficient infiltration capability,immunosuppressive microenvironments,and poor therapeutic response in solid tumors.With the in-depth exploration of tumor immunology and the development of genetic engineering technology,various new strategies have been attempted to enhance the efficacy and generalizability of CAR-T cell therapy.This paper presents a commentary on CAR-T cell therapy,with a focus on key clinical issues and corresponding countermeasures,providing valuable insights for future basic research and clinical transformation of CAR-T cell therapy.
